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Summary: The interaction between Bacillus Calmette-Guerin (BCG) and the host was investigated after
repeated intravesicular BCG-therapy for superficial bladder cancer. Studies were performed on
(a) the local reaction in the bladder,
(b) the systemic reaction, and
(c) short and long term interactions in both the bladder and the serum/plasma.
The analytes measured included anti-BCG IgA and IgG, fibronectin, lactoferrin, elastase-oci-proteinase
inhibitor, myeloperoxidase and oc2-proteinase inhibitor. All analytes, with the exception of oc2-proteinase
inhibitor, were measured in both serum/plasma and urine.
An additional group of 94 patients undergoing bronchoalveolar lavage was used for comparison with other
diseases affecting mucous membranes. In vitro studies on human bladder in culture were also carried out to
study the relationship between BCG, elastase and fibronectin.
The results revealed a normal defence reaction, in which IgA and IgG antibodies specific to BCG were
produced by the host. Maximal concentrations of all analytes in urine were found about 4 h after BCG
instillation.
Immunoglobulins, soluble fibronectin, and granulocyte markers all appeared in urine after instillation and all
showed a similar time course. The in vitro study showed the synergistic effect of elastase and BCG in
stimulating the host defence reaction. The relationship between BCG and fibronectin can be seen as fortuitous
but not indicative of the efficacy of BCG-therapy in patients with superficial bladder cancer.
Introduction (2—4), the necessity for the presence of a fibrin clot
(3, 5), the saturation of BCG receptors with soluble
Although post-operative intravesicular treatment of monomeric fibronectin (6), and the mediation of T-
superficial bladder cancer with Bacillus Calmette- lymphocytes (7). Studies in these laboratories over the
Guerin (BCG) has been carried out for some 15 years past four years have revealed further physiological
(1) the exact mode of action of this therapy is still factors which may contribute to the action of BCG
not known. Many theories have been postulated, in- in promoting an "anti-tumour" reaction in cases op-
eluding the interaction between BCG and fibronectin erated for superficial bladder cancer.
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The studies were carried out to investigate
(a) the nature of the immune response and its rela-
tionship to time, as well as to repeated BCG in-
stillation,
(b) the relationship between BCG and fibronectin,
and
(c) the role of leukocyte infiltration and leukocyte
products — especially proteinases — in creating
an optimal milieu for bladder wall permeation of
BCG and the initiation of antigen-antibody reac-
tions.
Tab. la. Immunoluminometric assay of urinary fibronectin
10 μΐ sample
200 μΐ assay buffer
1 Anti fibronectin coated ball (rabbit-IgG fraction)
Incubate at ambient temperature (18-25°C) for 60 min on
horizontal rotator (170 min'1).
Wash with 2 χ 5 ml demineralised water.
200 μΐ ABEN-labelled anti fibronectin (goat-IgG fraction)
Incubate and wash as above, transfer ball to measuring cuvette,
add 300 μΐ catalase and load luminometer.
Initiate light reaction with NaOH/H2O2 and integrate signal
over 2 s.
Materials and Measurements
Materials
Antibodies to BCG, fibronectin, human IgG and IgA, elastase,
arproteinase inhibitor, oc2-proteinase inhibitor, lactoferrin and
myeloperoxidase were purchased either from DAKO (Ham-
burg, D), Serotec (Camon, Wiesbaden, D) or Atlantic Anti-
bodies (Baxter, Munich, D). All were used as purified IgG
fractions and were, according to the manufacturers, "mono-
specific" in nature. No further purification was carried out.
Labelling was carried out using either a biotin derivative (8) or
the luminogen 9-[4-aminobutyl-N ethylj-aminobenzo (f) phthal-
azine 1,4, (2H,3H) dione (ABEN (9)) as published in detail
elsewhere. Assays were carried out using polystyrene balls (6.4
mm diameter) as solid phase (Spherotech Kugeln, Fulda, D).
Measurements were performed in a 250 sample semiautomatic
luminometer with on-line data reduction (LB 952 16T, EG & G
Berthold, Wildbad, D).
Methods
The analyses were carried out using immunoluminometric
assays (10). The analytes included:
antibodies to BCG (human class IgA and IgG),
antibodies to fibronectin (human class IgA and IgG),
Tab. Ib. Immunoluminometric assay to measure specific anti-
bodies to BCG
10 μΐ sample (undiluted urine, serum IgA 1 : 5/1 :10, IgG
1 :10/1 : 20)
200 μΐ assay buffer
1 ball with BCG covalently coupled antigen mixture
Incubate and wash as in table la above.
200 μΐ ABEN labelled anti serum IgA or IgG.
Incubate and wash as above, transfer ball to cuvette and pro-
ceed as in table la, integrating the light signal for 4 s.
fibronectin, albumin, transferrin, elastase, αι-proteinase inhib-
itor, a2-proteinase inhibitor, lactoferrin and myeloperoxidase.
The solid phase was coated with antigens and antibodies as
previously described (8 — 10).
The assay schemes for antibody detection and antigen detection
are shown in tables la and Ib for urinary fibronectin and anti-
BCG-IgA/IgG. The assay schemes for the other analytes were
similar.
Tab. 2. Ranges covered by assays, together with 95% confidence limits for healthy volunteers
Analyte
Elastase
Myeloperoxidase
Lactoferrin
Fibronectin
Anti BCG IgA
Anti BCG IgG
Measuring range
5-1900μβ/1
5-1200μβ/1
5-3000μg/l
10-2800μg/l
5- 100 U/l*
5- 100 U/l
95% confidence limits
<2^g/l
undetectable
<240μg/l
undetectable
<250μβ(1
< 20 μg/mmol
creatinine
250-600mg/l
< 30μg/mmol
creatinine
<110U/1*
6-18 χ 106U/mol
creatinine
<95U/1
8-40 χ 106U/mol
creatinine
Material
Plasma
Urine
Plasma
Urine
Plasma
Urine
Plasma
Urine
Serum
Urine
Serum
Urine
* U — arbitrary units
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Table 2 shows the concentration ranges covered by each assay
and the reference ranges in plasma and urine for healthy vol-
unteers.
Standards for the BCG-antibody assays were prepared from
antibody-positive urine. Standards for flbronectin were pre-
pared from human soluble flbronectin (Calbiochem — Behring,
Frankfurt a. M., D). Other standards were purchased or pre-
pared as necessary (8 — 10).
Experimental concepts and details
a) The detection of specific antibodies to BCG in the urine and
plasma of BCG-instilled patients — long and short term
studies
Patients were monitored,
1. in a longitudinal study over 12 months in which blood and
urine samples were taken before the BCG-instillation, and
2. in a short-term study covering the 24 hours starting directly
before the 6th instillation.
In the first case, 6 cycles of therapy were monitored for residual
antibody activity in blood and urine. In the 24 hour study,
blood and urine samples were collected directly before and at
5 additional times (2, 4, 6, 8 and 24 h) after the 6th instillation.
Although the 24 hour study was carried out for different in-
stillation cycles, only the results from the final cycle are shown
here. Total IgG and IgA were measured, as well as anti-BCG
specific IgG and IgA, in both serum and urine.
b) Detection of soluble flbronectin in urine and plasma in patients
undergoing BCG-therapy
Flbronectin was measured using the same two time regimes
described for BCG-antibodies in a) above. Both long and short-
term studies using plasma and urine samples were carried out.
Detection of anti-fibronectin was always found to be negative.
c) Detection of the leukocyte markers, elastase-arproteinase
inhibitor complexes, lactoferrin and myeloperoxidase in
plasma and urine
The three markers for granulocyte infiltration and activity were
assayed in urine samples using the same patients and the same
two time regimes described in a) above.
or production of elastase-arproteinase inhibitor complexes,
flbronectin, myeloperoxidase and lactoferrin was studied.
<x2-Macroglobulin was chosen as a "serum specific analyte" to
monitor the presence/release of blood-vessel contents into the
medium.
Single pieces (ca. 5 mg) of healthy human bladder, obtained
during cystectomy, were immediately transferred to and incu-
bated in 5 ml RMPI 1640 medium pH 7.4 at 37 °C in the
presence of 5% CO2. RMPI 1640 medium alone served as
medium control. Bladder in isotonic Ringer solution pH 7.4
served as autolysis control. BCG (ca. 200 χ ΙΟ9 U/l), elastase
(final concentration 450 μg/l) and BCG and elastase were in-
cluded in three incubation chambers to investigate and simulate
in vivo situations. Bladder in Hank's medium served as tissue
control. After incubation, the pieces of bladder were embedded
for histology and sections stained with haematoxylin-eosin and
auromycin.
g) Comparison with other known diseases where granulocyte
activity is detectable
Samples of bronchoalveolar lavage from patients with acute
pulmonary disease (sepsis, inflammation) and non-inflamma-
tory lung disorders were analysed for the three granulocyte
markers (see c) above) as well as for soluble fibronectin.
The studies were carried out over a four year period, the most
important results being summarised in this publication.
Statistics
Non-parametric statistics were used throughout. For the small
numbers of patients in each group the χ2 test was replaced by
the exact Fisher test, which is designed for studies with η < 60
data. The Mann-Whitney U-Test was used for independent
variables, the Wilcoxon signed rank test for paired data, and
the Spearman rank correlation for the investigation of con-
cordance between two related groups. The median was used as
the central tendency, together with the relevant percentiles as
measures of dispersion.
Results
d) Detection of serum-specific analytes in urine to confirm/ex-
clude microhaematuria
a2-Proteinase inhibitor, transferrin and IgG were measured in
serum and urine, in order to detect any lesions in the bladder
or ureter which would lead to "false positive" values for fibro-
nectin in urine. The ratio between these proteins in serum and
in urine confirms the presence or absence of their passive
transfer from the blood stream into the bladder. Only data
from patients, in which haematuria had been excluded, were
used in this study.
e) Control with patient groups with benign bladder disorders and
with healthy volunteers
Controls were chosen from patients with urosepsis, cystitis and
other benign bladder disorders, as well as healthy individuals
who showed a normal urine sediment.
f) In vitro studies on the interaction of BCG with elastase and
with flbronectin in human bladder culture
The production/interaction of BCG, fibronectin and elastase
was studied in vitro, using sterile, freshly isolated human blad-
der pieces in culture over a 24 hour period. The presence and/
1) The course of anti-BCG antibody produc-
tion in the bladder during BCG therapy
and the appearance of specific anti BCG
immunoglobulins in blood
During the course of six instillations of BCG at 4
week intervals, IgA and IgG antibodies to BCG meas-
ured prior to instillation were as shown in figure 1.
The time course of production of antibodies was
followed for 24 h after the 6th instillation by meas-
uring the IgA and IgG contents in the urine voided
at the time intervals shown. Both total immunoglob-
ulins and BCG-specific immunoglobulin antibodies
were measured. The BCG-specific antibodies are
shown in figure 2a (urine) and figure 2b (serum). The
total IgA and IgG in serum did not change during
therapy or after instillation. The IgA and IgG in urine
was almost exclusively anti-BCG-specific.
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Fig. 1. Anti BCG IgA and IgG in serum and urine during
instillation therapy.
Time course of antibody titres to BCG in serum and
urine. The measurements were made prior to each in-
stillation (1st—6th week) and at the control check-ups 3,
6, 9 and 12 months after the start of therapy.
• IgA, urine
* IgA, serum
+ IgG, urine
D IgG, serum
Only IgA and IgG specifically directed against a BCG-
homogenate were measured. The median values from
10 patients are shown. Due to large individual differ-
ences, no dispersion parameters are shown.
2) Concentrations of fibronectin in the urine
of patients under the same treatment as in
(1) above
The immunoluminometric assay was capable of meas-
uring less than 15 g/l and was therefore ideal for
urinary estimations. Figure 3 shows the median con-
centrations of urine fibronectin in 12 patients after
the 6th instillation (over 24 h). The concentrations of
soluble fibronectin found in urine before each instil-
lation were constant (25 ± 4 mg/mol creatinine).
There was no significant difference between the values
before each instillation (p > 0.7). As stated above,
antibodies to soluble fibronectin were never found in
urine.
Before 0
treat-
ment
2 4 S 8
Time after instillation [h]
Fig. 2. Anti BCG IgA (·) and IgG (0) in urine (a) and serum
(b) after the 6th instillation.
The acute response to BCG instillation in the bladder
is shown. Anti-BCG specific IgA and IgG were meas-
ured before and up to 24 hours after the 6th BCG
instillation.
Before treatment — values before commencement of
treatment (pre 1st instillation),
0 — value directly before the 6th instillation,
Only IgA and IgG specifically directed against a BCG-
homogenate were measured. The median values from
10 patients are shown. Due to large individual differ-
ences, no dispersion parameters are shown.
3) The production of the leukocyte compo-
nents, elastase, myeloperoxidase and lac-
toferrin during BCG instillation, and their
relationship to fibronectin and anti-BCG
The invasion of the bladder by leukocytes (mainly B
lymphocytes and polymorphonuclear neutrophils),
after instillation, led to the appearance of known
markers for these cells both longitudinally and over
24 hours.
The results for the 24 h study are shown in figure 3
and are median values for 12 patients undergoing the
same treatment as in (1) above. Direct leakage of
serum is excluded, because transferrin, IgG and a2-
proteinase inhibitor concentrations in urine do not
change significantly during the 24 hour period studied
(results not shown). The levels before instillation were
not significantly different from those found in urine
from hospitalised patients without known bladder
disease.
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Before
treat-
ment
4 6
Time after instillation [h]
α
Fig. 3. Urinary concentrations of fibronectin, lactoferrin, myeloperoxidase and elastase-ocrproteinase inhibitor complex after the
6th instillation.
The release/appearance of fibronectin, lactoferrin, myeloperoxidase and elastase-arproteinase inhibitor complex in urine
directly before and up to 24 h after the 6th BCG instillation is shown. Note that only elastase complexed with at-proteinase
inhibitor was measured; free elastase was not determined. The results are the median values from 12 patients.
4) Interaction between BCG and elastase in
vitro
Figures 4a—4e show the concentrations in the differ-
ent incubation chambers for elastase-ai-proteinase in-
hibitor complexes, lactoferrin, myeloperoxidase, fi-
bronectin and oc2-proteinase inhibitor respectively. As
the medium contained 530 μ§/1 fibronectin (Fig. 4c)
this concentration was subtracted from the actual
concentrations in each well so that the net production
of fibronectin is shown in figure 4c.
As was to be expected, the medium itself showed no
changes in concentration and little or no native ana-
lyte (with the exception of fibronectin).
The results in the well containing bladder and Ringer
solution showed that autolysis took place, the most
marked results being those for myeloperoxidase, oc2-
proteinase inhibitor and fibronectin. The histology
confirmed the autolysis.
The well containing the RPMI 1640 medium and
bladder showed relatively little autolysis, only mye-
Tab. 3. Relationship between elastase, lactoferrin, myeloperoxidase and fibronectin in bronchoalveolar lavage in 94 patients with
pulmonary infection
a) Concentrations in μ§/1
Percentiles
2.5
16
Median
84
97.5
Range
Elastase
<5
5.2
26
121
2700
<5-3160
Lactoferrin
<5
25
87
577
5790
<5-10130
Myeloperoxidase
<5
7.0
28
420
13000
< 5 -46800
Fibronectin
20
100
260
640
9700
20-10000
b) Correlation coefficients (r)
Elastase
Elastase
Elastase
Lactoferrin
Lactoferrin
Myeloperoxidase
vs.
vs.
vs.
vs.
vs.
vs.
Lactoferrin
Myeloperoxidase
Fibronectin
Myeloperoxidase
Fibronectin
Fibronectin
= 0.519
= 0.795
= 0.592
= 0.721
= 0.520
= 0.622
ρ < 0.001 in all cases
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Fig. 4. Release of elastase-arproteinase inhibitor complexes
(a), lactoferrin (b), myeloperoxidase (c), fibronectin (d)
and otrproteinase inhibitor (e) into the culture medium.
Two controls were used — medium without bladder and
Ringer solution with bladder. The remaining wells con-
tained medium, bladder, and the substance(s) under test.
The culture was maintained at 37 °C under 20% O2/
75% N2/5% CO2 and sterile conditions. The concentra-
tion of the analyte is shown on the ordinate, the time
in culture on the abscissa.
All fibronectin values have been corrected for the
amount of fibronectin in the medium (« 530 μg/l).
oc2-Proteinase inhibitor is a marker of "serum leakage"
and is most prominent in the incubation containing
Ringer solution and bladder. It also reflects granulocyte
infiltration and other granulocyte markers (figs 4c—4e).
medium
Ringer/bladder
medium/bladder
BCG/bladder
elastase/bladder
BCG/elastase/bladder
loperoxidase, a2-proteinase inhibitor and fibronectin
being released into the medium.
The well containing the BCG showed continuous re-
lease of all 5 analytes, showing that in vitro BCG
leads to stimulation of the granulocytes present in the
biopsy material.
The well containing the polymorphonuclear granu-
locyte elastase showed less response than that with
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 30,1992 / No. 9
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BCG. The combined effect of BCG and elastase gave
rise to the largest responses in four analytes. Bacterial
contamination of the culture medium was negative
after 24 h so that non-specific effects can be excluded.
All concentrations are the mean of duplicate deter-
minations, as this experiment was carried out only
once.
5) The measurement of elastase, myeloperox-
idase, lactoferrin and fibronectin in bron-
choalveolar lavage of patients with pul-
monary infections
This was performed to see how the above mentioned
analytes acted in a natural infection process occurring
at a mucosal barrier. The 94 patients involved in the
study were undergoing routine lavage inspection. Ta-
ble 3 shows the ranges and median concentrations of
each analyte in μg/l as well as the correlation between
each component using the Spearman rank correlation
coefficient.
Again, direct leakage from serum can be excluded,
because the serum: lavage ratio of each analyte is not
constant.
Discussion
The discussion compares known facts (which are not
necessarily directly related to the bladder and BCG
therapy) with the results of the investigation.
BCG therapy only appears to work effectively with
live bacteria (11), so it can assumed that a vital
component is necessary for successful therapy. It is
known that BCG produces and releases a specific
fibronectin-binding protein (Μτ 32 000) which is ex-
tremely antigenic in nature (12) as well as fibronectin-
binding proteins (13, 14) of relative molecular mass
Afr85000.
It is known also that myeloperoxidase, one of the
neutrophil enzymes, can irreversibly oxidize fibronec-
tin and make it more susceptible for degradation by
elastase, another neutrophil enzyme (15).
In bacterial infection due to Gram-negative organisms,
plasma fibronectin decreases at an early stage (16).
Decreases have also been noted in pulmonary hyper-
tension after oesophageal cancer operations (17). In
both cases plasma elastase rose significantly showing
an inverse relationship between elastase and fibronec-
tion. Treatments which suppress elastase release, for
example administration of dexamethasone, result in
elevated fibronectin values in bronchial lavage (18).
Recent results using different cytokines have con-
firmed that the degradation of fibronectin in an ex-
tracellular matrix is largely due to polymorphonuclear
leukocyte elastase (19).
The effects of elastase on the degradation of basement
membranes may assist the extravasation of neutro-
phils in the process of inflammation (20).
Other bacteria such as Pseudomonas sp. and Vibrio
sp. produce structurally related elastases which are
able to degrade fibronectin, lactoferrin and ovomucin
(21).
Several deductions and postulates can be made from
these observations and the results of the present study.
The removal of fibronectin from the basal membrane
increases permeability to invading organisms possess-
ing elastase-like exoproteinases, as well as to granu-
locytes and polymorphonuclear leukocytes which re-
present the natural cellular defence system of the host.
The oxidation of fibronectin by myeloperoxidase in-
creases the susceptibility to degradation by elastase.
The mycobacteria have at least one specific fibronec-
tin binding protein which shows a long phylogenetic
association between host and invader. The attachment
of BCG to fibronectin has also been documented by
Ratliffand co-workers (3, 4) as well as other groups
(2, 6). This would provide the BCG with an anchor
so that its exoproteases can act to permeate the epi-
thelium, thus allowing invasion of the organism.
In the later phase of BCG "attack", as in the later
stages of the therapy, two reactions take place simul-
taneously: polymorphonuclear leukocytes of the host
defence system release elastase and myeloperoxidase,
while the mycobacteria release, amongst other things,
their fibronectin binding protein.
The following may be postulated:
The host defence cells release BCG-specific antibodies
of both IgA and IgG classes. The IgA antibodies
attach themselves to BCG and lead to lysis of the
mycobacteria.
The phagocytes release elastase, which dissolves not
only bacterial proteins but also host proteins, espe-
cially membrane-incorporated fibronectin, which then
competes with insoluble fibronectin for the BCG.
The good correlation between both bladder polymor-
phonuclear granulocyte elastase and lavage elastase
and fibronectin concentrations tends to support the
fact that the polymorphonuclear granulocyte elastase
is probably responsible for the soluble fibronectin
(19).
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The production of antibodies to surface components
of BCG, as well as to internal proteins (12) leads to
the following proposal.
The BCG which permeate or infiltrate the bladder
wall are attacked by the natural host reaction, i. e. by
anti-BCG immunoglobulins if the BCG is free in the
bladder, or by phagocytes and T-cells if surrounded
by tissue (granulomata).
The results from the isolated bladder experiments
support the theory that although elastase alone leads
to the production of fibronectin, the presence of BCG
is necessary to initiate the activation of the leukocytes.
This is reflected by the fact that the production of the
analytes in the presence of elastase and BCG is greater
than the sum of the products when elastase and BCG
are added separately.
Another interesting feature of the in vitro study on
fresh isolated bladder is that the leukocytes reacted
exactly as in vivo, despite the fact that no perfusion
was performed. The release of contents or opening of
the blood vessels to the medium was well documented
by the behaviour of oc2-proteinase inhibitor, both in
medium and Ringer solution.
The rapid appearance of this analyte reflected the
autolysis process occurring in this control and ex-
plained the rapid appearance of some granulocyte
products in the Ringer solution. The rate of their
appearance also reflected the osmotic stability of the
granula in which they are stored.
The results are in accordance with the isolated obser-
vations listed above and appear to explain the rela-
tionship between BCG and fibronectin in BCG in-
stillation in the bladder.
Two types of response are seen in BCG instillation
therapy:
a) The normal antigen-antibody response reflected in
the production of IgA and IgG antibodies is spe-
cifically directed against BCG. This immune re-
action type is typical for bacterial invasion via the
mucosal membranes.
b) An indirect (Type IV) reaction is seen in the for-
mation of granulomata in the bladder epithelium.
This reaction is typical for mycobacteria.
The normal immunogenic reaction occurs as a re-
sponse to the repeated instillation of large numbers
of BCG, and it follows the typical course seen in
immunisation, i. e. primary response (IgA production
at mucous membrane barriers) followed by the long-
term response (IgG production) (see fig. 1; bi-phasic
response of antibody production). The type IV reac-
tion may explain the anti-tumour effect of BCG ther-
apy, since phagocytes and T-cells are both involved.
If the granuloma also includes tumour cells, it is
possible that the phagocytosis releases antigens or
"tumour-cell epitopes", which are then recognised as
"foreign" and thus give rise to a second, independent
"immunisation process", leading to production of an-
tibodies to tumour cell components.
Although this can be seen as being mediated by the
BCG therapy, it is completely independent of it as far
as the actual immune response is concerned.
The lymphocytes then not only recognise BCG but
also anti-cell surface antibodies which leads to the
lysis and destruction of the tumour cells. This is also
seen in adjuvant tumour therapy, where the host re-
ceives his own tumour cells in an "appetising" form
for phagocytes.
In such a case the role of fibronectin in BCG therapy
can be seen as minimal and the relationship between
BCG and fibronectin as phylogenetically historical
and almost fortuitous in nature.
The bacterium binds the fibronectin to invade the
host; at the same time the host sets in motion a
"fibronectin solublisation process" to prevent the bac-
terium from being able to adhere to the epithelial
cells, its specific binding protein being saturated with
soluble fibronectin.
This would not only explain the results seen here, but
would also explain the differing virulence of myco-
bacteria which appears to depend on the amount of
fibronectin binding protein that they produce.
It also explains why dead BCG have little or no
therapeutic effect as they are unable to permeate or
attach to the epithelium and set the immune reaction
in motion.
Conclusions
To conclude, it appears that to some extent the as-
sumed obligatory association between BCG and fi-
bronectin is mistaken, as far as explaining the mode
of action of BCG instillation therapy is concerned.
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